VIS-101 / Aosaikang Pharma, AffaMed Therap, Everest Medicines, NovaBridge Biosciences - LARVOL DELTA

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study (GlobeNewswire) - "VIS-101 produced rapid and robust efficacy, and durable treatment responses with both 3 mg and 6 mg dose cohorts: Mean improvement in Best Corrected Visual Acuity (BCVA) of >10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters; Median central subfield thickness (CST) reduction of 100-150 mm; Potential best-in-class durability with: ~two thirds of patients retreatment-free at 4 months; ~half of patients retreatment-free at 6 months; Favorable safety and no dose limited toxicity...'Such strong clinical results provide a meaningful foundation to advance our development program, including plans to initiate a dose-determining Phase 2b study in the second half of this year, followed by a global Phase 3 program in 2027.'"

New P2b trial • New P3 trial • P2a data • Wet Age-related Macular Degeneration

NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 (GlobeNewswire)

P2a data • Wet Age-related Macular Degeneration

Everest Medicines…has acquired an exclusive license with Visara, Inc., a subsidiary of NovaBridge Biosciences (formerly known as I-Mab), to secure an exclusive license to develop, manufacture and commercialise VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries. (Biospectrumasia) - "Under the assigned exclusive license, Everest Medicines will make an upfront payment of $7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to $89 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales....VIS-101 is anticipated to be Phase 3-ready in 2026."

Licensing / partnership • New P3 trial • Diabetic Macular Edema • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: AskGene Pharma, Inc. | Recruiting ➔ Active, not recruiting | N=36 ➔ 56 | Trial completion date: Apr 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of ASKG712 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: AskGene Pharma, Inc. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

Phase 1 Study of ASKG712 (Anti-VEGF-A/Ang-2 Bispecific Antibody) for Diabetic Macular Edema (DME) (ARVO 2025) - P1 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

P1 data • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Safety, Tolerability and Efficacy of Intravitreal AM712 for Neovascular Age-Related Macular Degeneration (CONQUER) (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Safety and Efficacy of AM712 in Patients with NAMD (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: AffaMed Therapeutics Limited | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Nov 2024 | Trial primary completion date: Jun 2024 ➔ Nov 2024

Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of ASKG712 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: AskGene Pharma, Inc.

New P1 trial • Diabetic Macular Edema • Ophthalmology

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: AskGene Pharma, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2022 ➔ Feb 2023

Enrollment open • Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: AskGene Pharma, Inc.

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Efficacy of AM712 in Patients With nAMD (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AffaMed Therapeutics (US) Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Efficacy of AM712 in Patients With nAMD (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: AffaMed Therapeutics (US) Inc.

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration